| Dual antiplatelet therapy is not optimal for stroke prevention in patients with atrial fibrillation. | |
| | |
MedLine Citation:
|
PMID: 20088990 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The superior efficacy of oral anticoagulation over aspirin for prevention of recurrent stroke in patients with atrial fibrillation is widely acknowledged. However, oral anticoagulation therapy is notorious for having a narrow therapeutic index, numerous drug and dietary interactions, and a significant risk of serious bleeding. The value of dual antiplatelet therapy for stroke prevention in patients with atrial fibrillation has been assessed in the ACTIVE A trial. In this study, the relative risk of primary events was significantly decreased in patients allocated clopidogrel and aspirin compared with patients receiving aspirin alone. However, the relative risk of major bleeding was also significantly increased. This article analyses critically the role of dual antiplatelet therapy for stroke prevention in patients with atrial fibrillation. |
| | |
Authors:
|
A Chamorro |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International journal of stroke : official journal of the International Stroke Society Volume: 5 ISSN: 1747-4949 ISO Abbreviation: Int J Stroke Publication Date: 2010 Feb |
Date Detail:
|
Created Date: 2010-01-21 Completed Date: 2010-03-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101274068 Medline TA: Int J Stroke Country: England |
Other Details:
|
Languages: eng Pagination: 28-9 Citation Subset: IM |
Affiliation:
|
Comprehensive Stroke Center, Hospital Clinic, University of Barcelona, Institut d'Investigacions Biom?diques August Pi i Sunyer, Barcelona, Spain. achamorro@ub.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Atrial Fibrillation
/
complications* Drug Therapy, Combination Humans Platelet Aggregation Inhibitors / adverse effects*, therapeutic use* Risk Factors Stroke / complications*, prevention & control* Vitamin K / antagonists & inhibitors |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors; 12001-79-5/Vitamin K |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hand up! Yawn and raise your arm.
Next Document: Microalbuminuria in cerebrovascular disease: a modifiable risk factor?